Circulating soluble IL-6 receptor associates with plaque inflammation but not with atherosclerosis severity and cardiovascular risk
Vascular Pharmacology · 2023-10 · 152 · 107214
DOI: 10.1016/j.vph.2023.107214 ↗Kurz gefasst
Fachartikel in der Zeitschrift Vascular Pharmacology, 2023-10. Verfasst von Andreas Edsfeldt und 8 weiteren Autor:innen. Beteiligte Einrichtung: Department of Clinical Sciences Malmö, Lund University, Sweden; Department of Cardiology, Skåne University Hospital, Sweden; Wallenberg Center for Mo…. Hauptthemen laut MEDLINE: Cardiovascular Diseases, Atherosclerosis, Myocardial Infarction. Die Arbeit wurde bisher 12-mal zitiert (Crossref) und nennt 41 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Stiftelsen för Strategisk Forskning, Region Skåne, Svenska Sällskapet för Medicinsk Forskning.
Abstract (Originalsprache)
BACKGROUND: The residual cardiovascular risk in subjects receiving guideline-recommended therapy is related to persistent vascular inflammation and IL-6 represents a target for its treatment. IL-6 binds to receptors on leukocytes and hepatocytes and/or by forming complexes with soluble IL-6 receptors (sIL-6R) binding to gp130 which is present on all cells. Here we aimed to estimate the associations of these two pathways with risk of cardiovascular disease (CVD). METHODS: IL-6 and sIL-6R were analyzed using the proximity extension assay. Baseline plasma samples were obtained from participants in the prospective Malmö Diet and Cancer (MDC) study (n = 4661), the SUMMIT VIP study (n = 1438) and the Carotid Plaque Imaging Project (CPIP, n = 285). Incident clinical events were obtained through national registers. Plaques removed at surgery were analyzed by immunohistochemistry and biochemical methods. RESULTS: During 23.1 ± 7.0 years follow-up, 575 subjects in the MDC cohort suffered a first myocardial infarction. Subjects in the highest tertile of IL-6 had an increased risk compared to the lowest tertile (HR and 95% CI 2.60 [2.08-3.25]). High plasma IL-6 was also associated with more atherosclerosis, increased arterial stiffness, and impaired endothelial function in SUMMIT VIP, but IL-6 was only weakly associated with plaque inflammation in CPIP. sIL-6R showed no independent association with risk of myocardial infarction, atherosclerosis severity or vascular function, but was associated with plaque inflammation. CONCLUSIONS: Our findings show that sIL-6R is a poor marker of CVD risk and associated vascular changes. However, the observation that sIL-6R reflects plaque inflammation highlights the complexity of the role of IL-6 in CVD.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Clinical Sciences Malmö, Lund University, Sweden; Department of Cardiology, Skåne University Hospital, Sweden; Wallenberg Center for Molecular Medicine, Lund University, Sweden.
- Department of Clinical Sciences Malmö, Lund University, Sweden; Department of Cardiology, Skåne University Hospital, Sweden.
- Department of Clinical Sciences Malmö, Lund University, Sweden.
- Diabetes and Vascular Medicine, University of Exeter Medical School and NIHR Exeter Clinical Research Facility, Exeter, UK.
- Department of Clinical and Experimental Medicine, University of Pisa, Italy.
- Division of Systems Medicine, University of Dundee, Dundee, UK.
Förderung
- Stiftelsen för Strategisk Forskning
- Region Skåne
- Svenska Sällskapet för Medicinsk Forskning
- Innovative Medicines Initiative
- Hjärt-Lungfonden
- NIHR Exeter Clinical Research Facility
- Knut och Alice Wallenbergs Stiftelse
- Vetenskapsrådet
Zitieren
APA
Edsfeldt, A., Gonçalves, I., Vigren, I., Jovanović, A., Engström, G., Shore, A. C., Natali, A., Khan, F., & Nilsson, J. (2023). Circulating soluble IL-6 receptor associates with plaque inflammation but not with atherosclerosis severity and cardiovascular risk. Vascular Pharmacology, 152, 107214. https://doi.org/10.1016/j.vph.2023.107214
Vancouver
Edsfeldt A, Gonçalves I, Vigren I, Jovanović A, Engström G, Shore AC, et al. Circulating soluble IL-6 receptor associates with plaque inflammation but not with atherosclerosis severity and cardiovascular risk. Vascular Pharmacology. 2023;152:107214. doi:10.1016/j.vph.2023.107214
BibTeX
@article{Edsfeldt2023,
author = {Edsfeldt, Andreas and Gonçalves, Isabel and Vigren, Isa and Jovanović, Anja and Engström, Gunnar and Shore, Angela C and Natali, Andrea and Khan, Faisel and Nilsson, Jan},
title = {Circulating soluble IL-6 receptor associates with plaque inflammation but not with atherosclerosis severity and cardiovascular risk},
journal = {Vascular Pharmacology},
year = {2023},
volume = {152},
pages = {107214},
doi = {10.1016/j.vph.2023.107214}
}
EUVIMED